



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

SP 99P-5330/CP 1

MAR 20 2000

Mark L. Shepard, M.S.
Vice President
Shotwell & Carr, Inc.
3535 Firewheel Dr., Suite A
Flower Mound, TX 75028-2628

Dear Mr. Shepard:

We refer to your suitability petition filed December 3, 1999, on behalf of Tyler Group, Inc., in which you requested permission to submit an abbreviated new animal drug application (ANADA) for a generic product with a dosage form that differs from that of an approved new animal drug. The proposed pioneer product is Merial's Enacard® Tablets (enalapril maleate tablets) which is intended for use in dogs (NADA 141-015).

Your proposed product differs from the pioneer product in dosage form and therefore delivery method. The pioneer product is a tablet containing 5 mg enalapril maleate; whereas your proposed product is a palatable, chewable tablet containing 5 mg enalapril maleate. The dosage of active ingredient per pound of body weight will be the same.

Change in dosage form is one of the five variances in the pioneer product which can be considered through a suitability petition under section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA), as amended. We are required to approve the petition unless we determine that investigations must be conducted to establish the safety and effectiveness of the proposed generic product.

Your suitability petition is approved. Approval of the suitability petition does not alter the requirements for approval of the ANADA, nor assure approval of the ANADA.

In addition to the study to show bioequivalence between the pioneer and generic products, we may require you to conduct a palatability study with the generic product. Palatability is not directly related to effectiveness. Palatability studies may be required in an ANADA with regard to the change in dosage form under section 512(n)(1)(D) of the FFDCA. We recommend that you submit protocols for our evaluation before initiating any studies.


We will conduct a definitive labeling review when the ANADA for the proposed generic product is submitted to the Center. The generic labeling should be a verbatim copy of the approved labeling for the pioneer, with certain allowable differences, such as directions for administration of the chewable tablet.

99P-5330

PAVI

You may contact Dr. Lonnie W. Luther, Chief, Generic Animal Drug and Quality Assurance Staff, (301) 827-0209, for any questions on the specific requirements for the ANADA submission.

Sincerely yours,

A handwritten signature in black ink, reading "Claire M. Lathers". The signature is fluid and cursive, with the first name "Claire" and last name "Lathers" being more prominent than the middle initial "M".

Claire M. Lathers, Ph.D., F.C.P.

Director

Office of New Animal Drug Evaluation

Center for Veterinary Medicine

MEMO

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR VETERINARY MEDICINE

8485 00 MAR 27 AM 106

DATE: 3/24/00

FROM: Animal Scientist
Quality Assurance Support Staff, HFV-102

SUBJECT: Suitability Petition Response for Display.

TO: Lyle Jaffe, HFA-305, 5630 Fishers Lane, rm. 1061, Rockville, MD
Dockets Management Branch, 301 827-6860 (V)

The attachment is the Center for Veterinary Medicine's letter related to Suitability Petition **SP 99P-5329CP 1**, and **SP 99P-5330CP 1**, Shotwell & Carr filed as a **Suitability Petitions**. We are forwarding copies for public display with the petition.

If you have any questions, please call me at 827-0211, or FAX 594-2297.

Thank you.

 03/24

Sam Hansard, Ph.D.

Attachment

Samuel Hansard, Ph.D.
FDA/CVM/ONADE/QASS/HFV-102
7500 Standish Place MPN II 384
Rockville, MD 20855
(301) 827-0211
(301) 594-2297 fax
shansard@cvm.fda.gov